Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGIRI vs regorafenib in metastatic colorectal cancer with Cyclin D1 A/A genotype
2018-002231-24Phase 3Active
- Sponsor
- Institut du Cancer de Montpellier
- Start
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in colorectal cancer (CRC) and metastatic colorectal adenocarcinoma (mCRC) comparing Regorafenib monotherapy with REGIRI (regorafenib + irinotecan) (2 arms). Primary endpoint: Overall survival. Started Jun 2018; status: active.
02
Drugs
regorafenibirinotecan
03
Conditions
colorectal cancer (CRC)metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2018-002231-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002231-24.